GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » PS Ratio

Keymed Biosciences (HKSE:02162) PS Ratio : 26.97 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Keymed Biosciences's share price is HK$39.40. Keymed Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.46. Hence, Keymed Biosciences's PS Ratio for today is 26.97.

The historical rank and industry rank for Keymed Biosciences's PS Ratio or its related term are showing as below:

HKSE:02162' s PS Ratio Range Over the Past 10 Years
Min: 18.52   Med: 49.68   Max: 180.61
Current: 26.99

During the past 5 years, Keymed Biosciences's highest PS Ratio was 180.61. The lowest was 18.52. And the median was 49.68.

HKSE:02162's PS Ratio is ranked worse than
71.57% of 999 companies
in the Biotechnology industry
Industry Median: 9.04 vs HKSE:02162: 26.99

Keymed Biosciences's Revenue per Sharefor the six months ended in Dec. 2023 was HK$0.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.46.

During the past 12 months, the average Revenue per Share Growth Rate of Keymed Biosciences was 246.30% per year.

Back to Basics: PS Ratio


Keymed Biosciences PS Ratio Historical Data

The historical data trend for Keymed Biosciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences PS Ratio Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - 40.88 119.16 33.13

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only 40.88 - 119.16 - 33.13

Competitive Comparison of Keymed Biosciences's PS Ratio

For the Biotechnology subindustry, Keymed Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keymed Biosciences's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's PS Ratio falls into.



Keymed Biosciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Keymed Biosciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=39.40/1.461
=26.97

Keymed Biosciences's Share Price of today is HK$39.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.46.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Keymed Biosciences  (HKSE:02162) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Keymed Biosciences PS Ratio Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Keymed Biosciences (HKSE:02162) Business Description

Traded in Other Exchanges
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Keymed Biosciences (HKSE:02162) Headlines

No Headlines